Cell infusions (intravenous or direct injection) are minimally invasive and cause few acute side effects; patients typically leave the same day. Biochemical changes in bone remodelling unfold over weeks to months, so meaningful clinical assessment requires 3–6 months minimum, with optimal evaluation at 12–18 months.
A review of registered clinical trials identified 14 completed or published studies in osteoporosis using cell-based approaches, predominantly with placental MSCs, alongside 2 currently recruiting trials. Trial sizes have ranged from 20 to 120 participants. Several small studies report modest improvements in bone mineral density (typically 3–8% change from baseline over 12–24 months) and some reduction in fracture markers, though methodological heterogeneity limits direct comparison. No large, multi-centre, phase III efficacy trial has yet reported.
Am I a candidate? → · Osteoporosis & Bone Health: full overview → · Osteoporosis & Bone Health cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita